{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-069368","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.123090+00:00","generated_at":"2026-06-22T07:11:47.810212+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jasper Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","bullets":["Nasdaq notice on Nov 3, 2022: bid price below $1.00 for 30 consecutive business days.","Company has 180 days (until May 2, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.","No immediate impact on listing; JSPR and JSPRW continue trading on Nasdaq Capital Market.","Options include reverse stock split if needed; company intends to monitor and consider available options.","Failure to cure may lead to delisting; possible appeal process but no assurance of relief."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-069368","json":"https://secwatch.observer/filing/0001213900-22-069368.json","markdown":"https://secwatch.observer/filing/0001213900-22-069368.md","text":"https://secwatch.observer/filing/0001213900-22-069368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022069368/0001213900-22-069368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022069368/ea168052-8k_jasperthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:11:47.810212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a566c92fc36fefd1a87c1f56816b7d4e9215636","claim":"Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"November 3, 2022, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until May 2, 2023, to regain compliance. The Not","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022069368/0001213900-22-069368-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}